Published in:
Open Access
01-06-2019 | Oral Antidiabetic Drugs | Original Research
Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
Authors:
Yasuo Terauchi, Kazunori Utsunomiya, Atsutaka Yasui, Tetsuo Seki, Gang Cheng, Kosuke Shiki, Jisoo Lee
Published in:
Diabetes Therapy
|
Issue 3/2019
Login to get access
Abstract
Introduction
Empagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by inducing urinary glucose excretion. Combination therapy with empagliflozin and glucagon-like peptide-1 (GLP-1) receptor agonists had not previously been assessed, so we investigated the safety, tolerability and efficacy of empagliflozin as an add-on therapy to liraglutide, a GLP-1 receptor agonist.
Methods
This was a randomised, double-blind, parallel-group phase 4 trial of empagliflozin (10 mg or 25 mg) for 52 weeks as an add-on therapy to liraglutide (0.9 mg/day) in Japanese patients with T2DM insufficiently controlled by liraglutide alone.
Results
59.4% (19/32) and 66.7% (22/33) of patients in the empagliflozin 10 mg and 25 mg groups, respectively, reported at least one adverse event (AE). 9.4% (3/32) and 21.2% (7/33) of patients, respectively, reported drug-related AEs (primary endpoint). From baseline to week 52, adjusted mean changes with empagliflozin 10 mg and 25 mg, respectively, were: − 0.55 (standard error: 0.15) and − 0.77 (0.14)% for glycated haemoglobin; − 32.5 (4.6) and − 36.0 (4.5) mg/dL for fasting plasma glucose; − 2.6 (0.4) and −3.1 (0.3) kg for body weight; − 6.7 (2.2) and − 8.4 (2.1) mmHg for systolic blood pressure; and − 3.0 (1.2) and − 4.7 (1.1) mmHg for diastolic blood pressure.
Conclusion
Empagliflozin as an add-on to liraglutide for 52 weeks was well tolerated and led to clinically meaningful and sustained improvements in glycaemic control, body weight and blood pressure in Japanese patients with T2DM.
Trial Registration
ClinicalTrials.gov with the identifier NCT02589626.
Funding
Nippon Boehringer Ingelheim Co. Ltd.